{"title":"Approach to Thrombocytopenia.","authors":"Tarinee Rungjirajittranon, Adam Cuker","doi":"10.1016/j.hoc.2026.09.010","DOIUrl":null,"url":null,"abstract":"<p><p>Thrombocytopenia ranges from benign to life-threatening, requiring a systematic evaluation including history, physical examination, peripheral blood smear review, and targeted laboratory testing. Pseudothrombocytopenia must be excluded. Mechanisms of thrombocytopenia include decreased platelet production, decreased survival, and splenic sequestration. In the inpatient setting, clinicians should consider postoperative thrombocytopenia, heparin-induced thrombocytopenia (HIT), other drug-induced thrombocytopenias, extracorporeal device-related causes, infection, and disseminated intravascular coagulation (DIC). In the outpatient setting, selected causes of thrombocytopenia include immune thrombocytopenia, chronic DIC, thrombotic thrombocytopenic purpura (TTP), and myelodysplastic syndrome, among others. Early recognition and prompt management of life-threatening conditions such as HIT and TTP is critical.</p>","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology-Oncology Clinics of North America","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.hoc.2026.09.010","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Thrombocytopenia ranges from benign to life-threatening, requiring a systematic evaluation including history, physical examination, peripheral blood smear review, and targeted laboratory testing. Pseudothrombocytopenia must be excluded. Mechanisms of thrombocytopenia include decreased platelet production, decreased survival, and splenic sequestration. In the inpatient setting, clinicians should consider postoperative thrombocytopenia, heparin-induced thrombocytopenia (HIT), other drug-induced thrombocytopenias, extracorporeal device-related causes, infection, and disseminated intravascular coagulation (DIC). In the outpatient setting, selected causes of thrombocytopenia include immune thrombocytopenia, chronic DIC, thrombotic thrombocytopenic purpura (TTP), and myelodysplastic syndrome, among others. Early recognition and prompt management of life-threatening conditions such as HIT and TTP is critical.
期刊介绍:
Hematology/Oncology Clinics updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Under the direction of an experienced guest editor, each issue focuses on a single topic in hematology and oncology, including hemostasis and thrombosis, molecular and cellular basis of hematology, coagulation disorders, and cancers—bone, gastrointestinal, head and neck, lymphomas, neuroendocrine, breast, renal cell, melanoma, and more.